You Lu, MD
West China Hospital
18
15
5
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+27 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Shun Dong Cang, MD
Henan Provincial People's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Lu Lu Su, MD
Henan Provincial People's Hospital
Shared therapeutic areas:
Worked with same sponsors:
Yue Xie, MM
Chongqing University Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shu Jie Li, MM
Chongqing University Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Qin Yu, MD
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
Li Zheng, MD
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
Maozhi Liang, MD
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
Feng Bi, MD
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
CongHua Xie, MD
Wuhan University
Shared therapeutic areas:
Worked with same sponsors:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Phase I Clinical Study of Metatinib Tromethamine Tablet
All 18 trials loaded